Moderna (MRNA) Competitors $27.08 +0.86 (+3.28%) Closing price 03:59 PM EasternExtended Trading$27.12 +0.05 (+0.17%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRNA vs. CRSP, CVAC, HOOD, NVAX, OCGN, TSLA, JNJ, MRK, PFE, and ARGXShould you be buying Moderna stock or one of its competitors? The main competitors of Moderna include CRISPR Therapeutics (CRSP), CureVac (CVAC), Robinhood Markets (HOOD), Novavax (NVAX), Ocugen (OCGN), Tesla (TSLA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), and argenex (ARGX). Moderna vs. Its Competitors CRISPR Therapeutics CureVac Robinhood Markets Novavax Ocugen Tesla Johnson & Johnson Merck & Co., Inc. Pfizer argenex CRISPR Therapeutics (NASDAQ:CRSP) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations. Which has more volatility & risk, CRSP or MRNA? CRISPR Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Which has better valuation and earnings, CRSP or MRNA? CRISPR Therapeutics has higher earnings, but lower revenue than Moderna. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCRISPR Therapeutics$35M141.11-$366.25M-$5.43-10.00Moderna$3.24B3.26-$3.56B-$7.53-3.60 Do insiders and institutionals have more ownership in CRSP or MRNA? 69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 11.0% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer CRSP or MRNA? In the previous week, Moderna had 11 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 19 mentions for Moderna and 8 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.99 beat Moderna's score of 0.56 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Moderna 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Do analysts prefer CRSP or MRNA? CRISPR Therapeutics presently has a consensus target price of $71.60, suggesting a potential upside of 31.85%. Moderna has a consensus target price of $42.88, suggesting a potential upside of 58.35%. Given Moderna's higher possible upside, analysts plainly believe Moderna is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRISPR Therapeutics 1 Sell rating(s) 6 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.50Moderna 4 Sell rating(s) 16 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04 Is CRSP or MRNA more profitable? Moderna has a net margin of -94.31% compared to CRISPR Therapeutics' net margin of -1,229.43%. CRISPR Therapeutics' return on equity of -20.05% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets CRISPR Therapeutics-1,229.43% -20.05% -17.09% Moderna -94.31%-25.96%-20.09% SummaryModerna beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks. Get Moderna News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRNA vs. The Competition Export to ExcelMetricModernaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.54B$3.09B$5.83B$9.73BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-3.6021.1631.1625.99Price / Sales3.26396.94474.86122.97Price / CashN/A43.0937.1558.38Price / Book1.128.069.116.38Net Income-$3.56B-$54.72M$3.26B$265.56M7 Day Performance-3.35%2.52%2.06%1.89%1 Month Performance-17.26%7.54%5.08%1.23%1 Year Performance-66.58%13.01%31.26%21.10% Moderna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRNAModerna4.4392 of 5 stars$27.08+3.3%$42.88+58.4%-69.7%$10.54B$3.24B-3.605,800Analyst ForecastCRSPCRISPR Therapeutics3.7962 of 5 stars$58.56-2.0%$71.60+22.3%+5.7%$5.32B$37.31M-10.78460CVACCureVac4.7153 of 5 stars$5.46-0.5%$6.83+25.3%+63.3%$1.22B$579.18M5.93880News CoverageEarnings ReportShort Interest ↓HOODRobinhood Markets3.9416 of 5 stars$113.76-0.4%$100.31-11.8%+426.8%$100.93B$2.95B57.652,300Positive NewsNVAXNovavax4.628 of 5 stars$10.02+4.5%$15.86+58.3%-41.0%$1.63B$1.08B4.391,990Analyst ForecastOCGNOcugen1.2294 of 5 stars$1.05-0.5%$6.00+474.2%-21.7%$305.45M$4.05M-5.2280TSLATesla4.382 of 5 stars$334.24+1.1%$303.31-9.3%+43.4%$1.08T$97.69B193.09125,665Trending NewsJNJJohnson & Johnson4.8247 of 5 stars$177.08+0.2%$174.50-1.5%+10.8%$426.43B$90.63B18.94138,100Trending NewsAnalyst ForecastMRKMerck & Co., Inc.4.9764 of 5 stars$84.54+0.4%$107.44+27.1%-25.8%$211.10B$64.17B13.0275,000Positive NewsPFEPfizer4.6639 of 5 stars$25.22+0.3%$28.12+11.5%-11.4%$143.30B$63.63B13.4181,000Trending NewsARGXargenex3.9034 of 5 stars$663.80+1.5%$746.81+12.5%+26.3%$40.62B$2.25B34.041,599Positive News Related Companies and Tools Related Companies CRISPR Therapeutics Alternatives CureVac Alternatives Robinhood Markets Alternatives Novavax Alternatives Ocugen Alternatives Tesla Alternatives Johnson & Johnson Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives argenex Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRNA) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moderna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moderna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access